Back to top
more

BioMarin Pharmaceutical (BMRN)

(Delayed Data from NSDQ)

$66.60 USD

66.60
1,644,379

+0.71 (1.08%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $66.63 +0.03 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Albireo (ALBO) Gets FDA Nod for Rare Liver Disease Drug

Following FDA approval, Albireo's (ALBO) Bylvay becomes the first drug to treat pruritus in PFIC.

Biotech Stock Roundup: REGN's Cocktail Approval, Updates From BMY, BMRN & VRTX

The biotech sector was in focus last week on updates form Regeneron (REGN) and Bristol Myers (BMY).

Vertex (VRTX) Initiates Phase II Study on Pain Candidate

Vertex (VRTX) starts phase II study for VX-548 to treat acute pain after bunionectomy surgery & expects to start another phase II study to treat acute pain after abdominoplasty surgery in a few weeks.

Synlogic's (SYBX) Begins Phase I Study for PKU Treatment

Synlogic (SYBX) initiates phase I study of SYNB1934, a synthetic biotic candidate to treat PKU. The drug is an evolved strain of SYNB1618, another PKU candidate currently undergoing phase II study.

BioMarin (BMRN) Gets EMA Validation for Hemophilia Gene Therapy

The EMA validates BioMarin's (BMRN) marketing application for valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.

QIAGEN (QGEN), Sysmex Ink Cancer Companion Diagnostics Deal

QIAGEN (QGEN) and Sysmex collaborate to develop and commercialize cancer companion diagnostics.

BioMarin (BMRN) Re-Files MAA for Hemophilia Gene Therapy in EU

Biomarin Pharmaceutical's (BMRN) new MAA in EU includes 52 weeks' data from the phase III GENEr8-1 study, along with four and three-year follow-up data from the ongoing phase I/II dose escalation study.

BioMarin's (BMRN) Vosoritide Gets CHMP Nod to Treat Dwarfism

Biomarin Pharmaceutical (BMRN) receives positive recommendation from Europe's CHMP for vosoritide to treat achondroplasia in children.

BioMarin (BMRN) Hemophilia Gene Therapy Gets EMA's Speedy Review

The EMA grants accelerated assessment to BioMarin's (BMRN) request for review of valoctocogene roxaparvovec for treating severe hemophilia A.

BioMarin (BMRN) Q1 Earnings Beat, FDA Delays Vosoritide Decision

BioMarin (BMRN) beats estimates for both earnings and revenues in the first quarter of 2021.

BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings and Revenue Estimates

BioMarin (BMRN) delivered earnings and revenue surprises of 75.00% and 9.11%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioMarin (BMRN) Down 7.7% Since Last Earnings Report: Can It Rebound?

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BioMarin (BMRN) Hemophilia Gene Therapy Gets FDA's RMAT Tag

FDA grants RMAT designation to BioMarin's (BMRN) gene therapy for severe hemophilia A, valoctocogene roxaparvovec, after rejecting it last year.

BioMarin (BMRN) Q4 Earnings Beat, 2021 Sales View Dull

BioMarin (BMRN) beats estimates for both earnings and sales in the fourth quarter. Sales guidance for 2021 falls short of investor expectation.

Earnings Preview: BioMarin Pharmaceutical (BMRN) Q4 Earnings Expected to Decline

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ALXN vs. BMRN: Which Stock Is the Better Value Option?

ALXN vs. BMRN: Which Stock Is the Better Value Option?

ALXN vs. BMRN: Which Stock Should Value Investors Buy Now?

ALXN vs. BMRN: Which Stock Is the Better Value Option?

Stock Market News for Jan 12, 2021

Benchmarks declined from record highs on Monday as investors weighed impact of rise in coronavirus cases and ongoing political turmoil on economic growth.

BioMarin (BMRN) Reveals 1-Year Data on Hemophilia Gene Therapy

BioMarin (BMRN) announces one-year update from GENEr8-1 phase III study, which shows that valoctocogene roxaparvovec significantly reduces annualized bleeding rate (ABR) by 84% in patients with hemophilia A.

ALXN or BMRN: Which Is the Better Value Stock Right Now?

ALXN vs. BMRN: Which Stock Is the Better Value Option?

The Zacks Analyst Blog Highlights: BioMarin Pharmaceutical, uniQure, REGENXBIO and Deciphera Pharmaceuticals

The Zacks Analyst Blog Highlights: BioMarin Pharmaceutical, uniQure, REGENXBIO and Deciphera Pharmaceuticals

4 Biotechs That Could Be Potential Acquisition Targets in 2021

We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2021.

Why Is BioMarin (BMRN) Up 6.1% Since Last Earnings Report?

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Pfizer (PFE) Begins Phase III Study on Hemophilia Candidate

Pfizer (PFE) doses the first participant in the late-stage BASIS study, currently investigating marstacimab to address severe hemophilia A or B with or without inhibitors.